Abstract: A series of new N-substituted derivatives of 3- [(5-{1-[(4-chlorophenyl)sulfonyl]-3-piperidinyl}-1,3,4-oxadiazol-2-yl)sulfanyl]propanamide (7a-q) was synthesized to evaluate new drug candidates for Alzheimer's disease. 4-Chlorobenzenesulfonyl chloride (a) and ethyl piperidin-3-carboxylate (b) were converted into 5-{1-[(4-chlorophenyl)sulfonyl]-3-piperidinyl}-1,3,4-oxadiazol-2-thiol (3) through a series of three steps. A series of electrophiles, N-alkyl/aralkyl/aryl-3-bromopropanamide (6a-q), was synthesized by gearing up 3-bromopropionyl chloride (5) with different alkyl/aralkyl/aryl amines (4a-q). Target compounds were synthesized by reacting compound 3 with different electrophiles, 6a-q, under basic conditions in an aprotic polar solvent. The synthesized compounds were subjected to spectral analysis, EI-MS, IR, 1
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PUBLIC INTEREST STATEMENT
The increased level of resistance of diseasecausing microorganisms for the available drugs is an alarming issue in the whole world. This issue has been resolved up to a great extent by the current synthesized compounds which could be a solid effort in this contest.
Introduction
Oxadiazoles have been the centre of interest for chemists due to their versatile therapeutic potential for two decades. The heterocyclic 1,3,4-oxadiazoles and their derivatives are widely used as antituberculosis, antimicrobial and antimalarial (Holla, Poojary, Kalluraya, & Gowda, 1996; Shafi & Radhakrishnan, 1995; Tan et al., 2006) ; analgesic, anticonvulsant, antidepressant and anti-HIV (Aziz-ur-Rehman, Fatima, Abbas, et al., 2013; Goswami, Kataky, & Baruash, 1984) ; anticancer and anti-inflammatory (Matsumoto et al., 1998; Omar, Mahfouz, & Rahman, 1996) ; anti-mycobacterial (Sharma & Jain, 2008a , 2008b Wagle, Vasudeva, & Suchetha, 2008) , antibacterial (Khalid et al., 2016) and anti-enzymatic activities. Another heterocyclic core, piperidine is known to possess anti-cancer, analgesics, anti-HIV, antidepressants, antibacterial, anti-histaminic and anti-fungicidal activities (Castro, Camarasa, Balzarini, & Velazquez, 2014; Khobare et al., 2015; Vitnik & Vitnik, 2015) . Sulfonamides are widely used as drugs due to their anti-inflammatory, antimicrobial, anti-diuretic and anti-thyroid potential (Aziz-ur-Rehman, Fatima, Abbas, et al., 2013; , 2016 El-Sayed, ElBendary, El-Ashry, & El-Kerdawy, 2011; Ordonez et al., 2011; Zoumpoulakis et al., 2012) .
Cholinesterases belong to a class of enzymes which include acetyl cholinesterase (AChE) and butyryl cholinesterase (BChE) enzymes. This class consists of serine hydrolase enzymes. Alzheimer's disease results in the loss of identification and poor memory. Loss of memory is the result of decline in neurotransmission in synaptic membrane. AChE causes hydrolysis of acetylcholine (ACh) into choline and acetate which inhibits the cholinergic neurotransmission in human brain and results in Alzheimer's disease. AChE performs main function to keep brain healthy by regulating the level of ACh in brain. AChE-inhibiting agents are required to maintain the level of acetylcholine in synaptic cleft to keep cholinergic neurotransmission smooth. Alzheimer's disease, Parkinson's disease and senile dementia can be treated by these inhibitors (Zhao et al., 2013) . Therefore, the search of new AChE inhibitors may lead to new potent drug candidates for the mentioned diseases.
Haemolysis is related to the breakdown of red blood cells (RBCs) and the ability of compounds to break RBCs is evaluated through haemolytic activity. Haemolytic activity describes the toxicity level of different substances. In drug development programmes, it is an important factor to study the biologically active compounds that the specified compounds are either toxic or nontoxic and what's the level of their toxicity.
In the presented research work, an effort was made to synthesize clinically active compounds by gearing up 1,3,4-oxadiazole, piperidine and sulfonamide linkages of great therapeutic potential in a single moiety. Presented manuscript is a continuation of our previous work Gul et al., 2013; Nafeesa et al., 2015 Nafeesa et al., , 2017 where differently S-substituted 1,3,4-oxadiazoles were synthesized and evaluated for biological activities. The previous work by our group on cholinesterase enzyme inhibition potential revealed that 2,5-disubstituted-1,3,4-oxadiazole derivatives exhibited good inhibition potential for the AChE enzyme Gul et al., 2013) . A series of derivatives of 1,3,4-oxadiazole have been synthesized with structural modification and subjected to AChE inhibitory activity to inaugurate more potent inhibitors. The structural modification has a key role in affecting the bioactivities of compounds (Modi & Modi, 2012) . The synthesized new series of N-substituted derivatives of 3- [(5-{1-[(4-chlorophenyl) sulfonyl]-3-piperidinyl}-1,3,4-oxadiazol-2-yl)sulfanyl]propanamide (7a-q) was also analysed for haemolytic potential to evaluate their level of toxicity.
Results and discussion
In the presented research work, a series of N-substituted derivatives of 3- [(5-{1-[(4-chlorophenyl) sulfonyl]-3-piperidinyl}-1,3,4-oxadiazol-2-yl)sulfanyl]propanamide (7a-q) has been synthesized by following multistep protocol sketched in Scheme 1. The varying substituents are listed in Table 1 .
The heterocyclic 1,3,4-oxadiazole, 5-[1-[(4-chlorophenyl) sulfonyl]-3-piperidinyl]-1,3,4-oxadiazol-2-thiol (3) was synthesized by three step protocol. The first step involved the reaction of ethyl nipecotate (b) and 4-chlorobenzene sulfonyl chloride (a) in basic aqueous media to synthesize ethyl 1-(4-chlorophenylsulfonyl)piperidin-3-carboxylate (1). This product was collected at neutral pH for maximum yield. The second step involved refluxing of 1 with hydrazine to acquire the corresponding carbohydrazide. The synthesized carbohydrazide, 2, was refluxed with carbon disulfide in alcoholic media in presence of potassium hydroxide to synthesize the heterocyclic 1,3,4-oxadiazole, 3. The product was filtered out from the solution with pH = 5-6. Low acidic pH was mandatory for maximum yield. The structure of compound 3 was characterized by IR spectrum with characteristic absorption band at 1591 cm −1 for C = N stretching and 1230, 1072 cm −1 for C-O-C stretching indicating the oxadiazole ring formation. Characteristic absorption of S-H group obtained at 2252 cm −1 . Parallel to this a series of N-alkyl/aralkyl/aryl-3-bromopropanamides (6a-q) was synthesized by the reaction of alkyl/aralkyl/aryl amines (4a-q) with 3-bromopropionyl chloride (5) in basic aq. medium. Target compounds were synthesized by gearing up compound 3 with these N-alkyl/aralkyl/aryl-3-bromopropanamides (6a-q) in aprotic solvent. IR spectra of these compounds revealed characteristic signals at 3340 for N-H stretching and 1660 for C = O stretching due to acid amide group with disappearance of S-H stretching. The 1 H-NMR spectra recorded in CDCl 3 at 300 or 400 MHz gave δ (ppm) around 7.70-7.64 and 7.52-7.47 as two doublets characteristic for p-chlorophenyl sulfonyl moiety with integration of two protons each. The characteristic two triplets of propanamide appeared at δ (ppm) 3.44-3.57 and 2.69-3.00 due to adjacent thiol and carbonyl groups, respectively. The (Gul et al., 2013) . Abbasi et al. synthesized 14 S-substituted derivatives of 5-(2-nitrostyryl)-1,3,4-oxadiazole-2-thiol but all the derivatives remained least active inhibitors of AChE enzyme than the parent molecule . The active compounds among these series suggested that further structural modification at second and fifth positions of 1,3,4-oxadiazole ring may lead to the inauguration of new potent molecules (Modi & Modi, 2012) . All the derivatives showed excellent-to-moderate inhibition activity against cholinesterase enzyme. Eserine was used as reference standard for AChE inhibition activity. Among the compounds 7c-h bearing dimethylphenyl groups, two compounds, 7g and 7h, showed better inhibitory potential against AChE with IC 50 values of 7.21 ± 0.04 µM and 5.76 ± 0.02 µM, respectively, with reference to Eserine, the reference standard, having IC 50 value of 0.04 ± 0.0.0001 µM. The better activity may be attributed to the presence of 3,4-dimethylphenyl and 3,5-dimethylphenyl groups due to collective electron donating inductive effect of two methyl groups. Both of these compounds bear one methyl group at meta position in common. Among the compounds bearing mono-substituted phenyl groups like 7b, 7k, 7l, 7p and 7q, only two compounds, 7l and 7p exhibited excellent AChE inhibitory activity with IC 50 values of 3.64 ± 0.01 µM and 7.62 ± 0.03 µM, respectively, as compared to the reference standard. The better activity of these compounds might be due to electron donating inductive and mesomeric effect of 4-ethylphenyl and 2-ethoxyphenyl groups respectively. Thus, the position and size of substituents has a considerable effect on the bioactivity of the synthesized compounds (Modi & Modi, 2012) . Three compounds 7o, 7f and 7d were the least active ones against AChE.
Haemolytic activity studies
All derivatives were analysed for their haemolytic activity with reference of positive control Triton-X and negative control phosphate buffer saline (PBS). The highest haemolytic activity was exhibited by the compounds 7q, 7b and 7h with % lysis values of 20.2, 19.5 and 19.0, respectively, but very much less than positive control Triton-X. The lowest haemolysis was revealed by compound 7m, 7p and 7n with % lysis values of 6.4, 6.5 and 7.3, respectively, but appreciably higher than that of negative control PBS. The most active compounds against AChE, 7l and 7p presented the least haemolytic activity of 9.8 and 6.5, respectively, but the other two compounds 7g and 7h showed higher value of haemolytic activity.
Conclusion
A new series of potent molecules as new drug candidates against Alzheimer's disease was synthesized and systematically characterized by EI-MS, IR, 1 H-NMR and 13 C-NMR. The screening of synthesized molecules for anti-enzymatic activity depicted their excellent-to-moderate behaviour. The most active compounds 7l, 7p, 7f and 7c bearing low % of haemolytic activity may be subjected to in vivo study for the treatment of Alzheimer's diseases. Some new derivatives with slight modifications may be synthesized in search of potential drug candidates. This may open more information for structure/ activity relationship and rational design of potent novel drug molecules.
Materials and methods

Material
Thin-layer chromatography was performed to assure the purity of all synthesized compounds. Ethyl acetate and n-hexane were used in different proportions as mobile phase. TLC was performed on pre-coated silica gel G-25-UV 254 plates. UV lamp at 254 nm was used to visualize the spots on TLC. Different chemicals and analytical solvents were purchased from local suppliers. Griffin and George melting point apparatus was used to take melting points by open capillary method. IR spectra were recorded by KBr pellet method on Jasco-320-A spectrophotometer. Mass spectra (EIMS) were recorded on JMS-HX-110 spectrometer. 1 H-NMR and 13 C-NMR spectra were recorded at 400, 300 and 100 MHz frequencies on Bruker spectrometers. Deuterated chloroform (CDCl 3 ) was used as solvent while TMS was the reference standard. Chemical shift values were presented in ppm unit.
Synthesis of ethyl 1-[(4-chlorophenyl)sulfonyl]piperidin-3-carboxylate (1)
Ethyl 1-[(4-chlorophenyl)sulfonyl]piperidin-3-carboxylate (1) was synthesized by the reaction of 4-chlorobenzene sulfonyl chloride (a; 0.05 mol) and ethyl piperidin-3-carboxylate (b; 0.05 mol) on stirring in aqueous medium for 4 h. Dynamic pH was maintained at 9-10 by addition of 5% solution of Na 2 CO 3 . Reaction completion was assured by thin layer chromatography. n-Hexane and EtOAc (70:30) mixture was used to develop TLC and visualized in UV light. On completion, the reaction mixture was neutralized and product was collected by solvent extraction method. The solvent was evaporated to acquire pure product.
Synthesis of 1-[(4-chlorophenyl)sulfonyl]piperidin-3-carbohydrazide (2)
Compound 1 (0.05 mol) was converted into 1-[(4-chlorophenyl)sulfonyl]piperidin-3-carbohydrazide (2) on reflux for 3 h with hydrated hydrazine (80%) in methanol. TLC was developed to confirm the completion of reaction. On completion of reaction, excess methanol was distilled off and reaction contents were cooled to room temperature. Cold distilled water was added to reaction mixture and product was quenched by simple filtration. Precipitates were thoroughly washed and dried.
Synthesis of 5-{1-[(4-chlorophenyl)sulfonyl]-3-piperidinyl}-1,3,4-oxadiazol-2-thiol (3)
5-(1-(4-Chlorophenylsulfonyl)-3-piperidinyl)-1,3,4-oxadiazol-2-thiol (3) was synthesized from compound 2 (0.06 mol) on reflux with CS 2 (0.12 mol) in ethanol in the presence of solid KOH (0.06 mol). Reaction mixture was refluxed for 5 h. To assure the reaction completion, TLC was developed in EtOAc and n-hexane. On reaction completion, excess ethanol was distilled off and cold distilled water was added to reaction mixture. Finally dil. HCl was used to acidify the reaction contents for pH of 4-5 to get maximum yield. Precipitates obtained were filtered and thoroughly washed with water.
4.5. General procedure for synthesis of n-alkyl/aralkyl/aryl-3-bromopropanamides (6a-q) N-Alkyl/aralkyl/aryl amines (4a-q; 0.03 mol) and 3-bromopropionyl chloride (5; 0.03 mol) were stirred in basic aqueous medium to obtain N-alkyl/aralkyl/aryl-3-bromopropanamides (6a-q). Sodium carbonate (5% aq. soln.) was used to control pH at 9-11. Vigorous stirring for 1 h resulted into the formation of product. Precipitates formed were simply filtered and liquid products were obtained by solvent extraction. Complete use of the reactants was confirmed by TLC.
General procedure for synthesis of n-alkyl
Compound 3 (0.2 g, 0.55 mmol) and equimolar N-alkyl/aralkyl/aryl-3-bromopropanamides (6a-q) were stirred in N,N-dimethylformamide (DMF) to acquire the target compounds. Compound 3 was dissolved in 10 mL DMF followed by LiH (0.55 mmol) and stirred for 0.5 h. The synthesized electrophiles, 6a-q, were added and the reaction mixture was further stirred for 3-4 h. The products were acquired through filtration, washed by distilled water and dried.
Cholinesterase enzyme inhibition assay
The AChE activity was performed according to the reported method (Ellman, Courtney, Andres, & Featherstone, 1961) .
Haemolytic activity
Haemolytic activity of the compounds was determined according to the reported method (Powell, Catranis, & Maynard, 2000; Sharma & Sharma, 2001 ).
Statistical analysis
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